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Abstract
Background: Network meta-analysis (NMA) has become a popular method to compare more than two treatments.
This scoping review aimed to explore the characteristics and methodological quality of knowledge synthesis
approaches underlying the NMA process. We also aimed to assess the statistical methods applied using the Analysis
subdomain of the ISPOR checklist.
Methods: Comprehensive literature searches were conducted in MEDLINE, PubMed, EMBASE, and Cochrane
Database of Systematic Reviews from inception until April 14, 2015. References of relevant reviews were scanned.
Eligible studies compared at least four different interventions from randomised controlled trials with an appropriate
NMA approach. Two reviewers independently performed study selection and data abstraction of included articles.
All discrepancies between reviewers were resolved by a third reviewer. Data analysis involved quantitative
(frequencies) and qualitative (content analysis) methods. Quality was evaluated using the AMSTAR tool for the
conduct of knowledge synthesis and the ISPOR tool for statistical analysis.
Results: After screening 3538 citations and 877 full-text papers, 456 NMAs were included. These were published
between 1997 and 2015, with 95% published after 2006. Most were conducted in Europe (51%) or North America
(31%), and approximately one-third reported public sources of funding. Overall, 84% searched two or more
electronic databases, 62% searched for grey literature, 58% performed duplicate study selection and data
abstraction (independently), and 62% assessed risk of bias. Seventy-eight (17%) NMAs relied on previously
conducted systematic reviews to obtain studies for inclusion in their NMA. Based on the AMSTAR tool, almost
half of the NMAs incorporated quality appraisal results to formulate conclusions, 36% assessed publication bias,
and 16% reported the source of funding. Based on the ISPOR tool, half of the NMAs did not report if an assessment for
consistency was conducted or whether they accounted for inconsistency when present. Only 13% reported
heterogeneity assumptions for the random-effects model.
Conclusions: The knowledge synthesis methods and analytical process for NMAs are poorly reported and need
improvement.
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Background
Remaining up-to-date on healthcare information is a
challenge with approximately 75 trials and 11 systematic
reviews being published daily [1]. Healthcare professionals
and decision-makers increasingly rely on knowledge syn-
theses, such as systematic reviews and meta-analyses, to
keep abreast of the literature and inform decisions based
on the totality of evidence [1, 2]. This may explain why
systematic reviews and meta-analyses have the highest
relative citation impact in health research [3]. However,
pairwise meta-analyses are limited by the availability of
randomised controlled trials (RCTs) that directly compare
one treatment relative to another. This can be particularly
problematic when comparing the efficacy of multiple com-
peting interventions, since it is unlikely that RCTs provide
direct comparisons for all interventions of interest [4–6].
To overcome this challenge, an extension to pairwise
meta-analysis that allows indirect comparisons of multiple
competing interventions in the absence of trials involving a
direct comparison have been proposed [7, 8]. The indirect
method implies that the information available from RCTs
of treatment A and treatment B can be compared via a
common comparator C (e.g., placebo or usual care) by sta-
tistically combining the information from RCTs comparing
A versus C and B versus C [4]. When a single model com-
bines information from both direct and indirect compari-
sons across a network of studies to infer the relative
efficacy and safety of multiple interventions, it constitutes
a network meta-analysis (NMA). Other terms used for
NMA include mixed-treatment comparisons meta-analysis
or multiple treatments meta-analysis [9, 10].
The use of NMA has increased rapidly since the mid-
2000s [4, 11, 12]. This rapid development has raised con-
cerns about the standardization and transparency of conduct
and reporting of NMA publications. Recent publications
from the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) [13, 14] and the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) extension statement for NMAs [15] have
attempted to offer education and guidance on optimal
conduct and reporting of NMAs. An overview of reviews
exploring the existing publications on quality of reporting in
NMAs found several deficiencies [16]. However, an in-depth
assessment of the conduct of the knowledge synthesis
approaches underlying the NMA is lacking. As such, we
aimed to explore the characteristics and methodological
quality of knowledge synthesis approaches of NMAs. We
also aimed to assess the statistical methods applied using
the Analysis subdomain of the ISPOR checklist [17].
Methods
Study protocol
A scoping review protocol was developed using the meth-
odological framework proposed by Arksey and O’Malley
[18], as well as the methods manual published by the Jo-
anna Briggs Institute Methodology for scoping reviews
[19]. The review protocol can be found in Additional file 1:
Appendix 1. This scoping review is related to another
methodological review that focused on the characteristics
and core statistical methodology specific to NMAs in clin-
ical research [20].
Eligibility criteria
We included NMAs that compared at least four different
interventions from RCTs using a valid statistical method
for indirect comparisons (e.g., adjusted or anchored indirect
comparison method [7, 13]) or NMAs (e.g., hierarchical
models). Studies that applied a naïve or invalid indirect
comparison approach failing to preserve within-study
randomization were excluded [21]. Studies of diagnostic
test accuracy and those including animals or only non-
randomized studies were also excluded. NMAs in which
the number of trials was smaller than the number of inter-
ventions were excluded. Both published and unpublished
reports in all languages of publication were eligible for
inclusion.
Information sources and literature search
An experienced library technician conducted compre-
hensive literature searches in MEDLINE, EMBASE,
PubMed, and Cochrane Database of Systematic Reviews
from inception until April 14, 2015. The MEDLINE
search strategy was developed in consultation with the
research team and peer-reviewed by an expert librarian
using the Peer Review of Electronic Search Strategies
(PRESS) checklist [22]. The final search strategy for the
MEDLINE database can be found in Additional file 1:
Appendix 2. The database search was supplemented
by manually searching the references of a relevant
systematic review [23] and a pre-existing database of
NMAs [11].
Study selection process
The screening criteria were established a priori and
calibrated amongst the team (AAV, AV, SS, PR, MP,
AN, AC) with a pilot-test on a random sample of 50
articles. After more than 90% inter-rater agreement
was established, pairs of reviewers screened the titles
and abstracts independently, and all discrepancies
were resolved by a third reviewer (AAV, PR, AC, GS).
The same process was followed when screening po-
tentially relevant full-text articles. All levels of screening
were performed using our proprietary online tool,
Synthesi.SR [24].
Data items and data abstraction process
A predefined data abstraction form was developed in
Excel. The abstracted data included study characteristics
Zarin et al. BMC Medicine  (2017) 15:3 Page 2 of 11
(e.g., author, publication year, country of corresponding
author, journal name, funding sources) and steps involved
in the knowledge synthesis conduct (e.g., protocol use,
inclusion criteria, literature search approach, screening
and data collection process, quality appraisal). We also
collected data on the terminology used to describe NMAs
and references of methodology papers that informed the
analysis.
The form was calibrated through two pilot-tests
amongst the team (WZ, VN, AV, ER, SM, JA, ACT)
on a random sample of seven included articles. For
this exercise, the team independently abstracted data
and a facilitated team meeting was held for feedback
and discussion on discrepant items. Upon completion
of the pilot-tests, pairs of reviewers (WZ, VN, AV,
ER, SM, JA) independently completed data abstraction
for the first 215 included articles. The remaining 241
included articles were abstracted by one reviewer and
verified by a second reviewer. All discrepancies be-
tween reviewers were resolved by a third reviewer
(WZ, VN).
Quality assessment of included NMAs
The quality of the knowledge synthesis methods was
appraised using the AMSTAR tool [25]. The AMSTAR
tool was created and validated to assess the methodo-
logical quality of systematic reviews of RCTs [26]. The
tool measures overall quality, where a score of 8 or
higher is considered high quality, 4 to 7 is moderate
quality, and 0 to 3 is low quality [27]. Information for
quality assessment was incorporated into the data
extraction form, which was pilot-tested on a random
sample of seven included articles that ranged from low
to high quality.
To appraise the validity of the analytical methods ap-
plied, we used the 6-item Analysis subdomain of the
ISPOR checklist for NMAs [17]. To ensure high inter-
rater agreement, a workshop on the tool was held with
the team and two pilot-tests were conducted on a ran-
dom sample of seven included NMAs. Each pilot-test
consisted of a facilitated team meeting for feedback
and discussion on discrepant items. Upon completion
of the pilot-tests, pairs of reviewers (AAV, WZ, JA, SS,
PR, CD, JE) independently assessed the first 215 in-
cluded articles. The remaining 241 included articles
were assessed by one reviewer (MP) and verified by a
second reviewer (AV, SS). All discrepancies were resolved
by a third reviewer (WZ, AAV). ISPOR items that were
not applicable to open loop networks (related terms in-
clude without a closed loop, star-shaped network, and
tree-shaped network) were scored as ‘not applicable'.
Items related to heterogeneity were also not applicable to
NMAs that used a fixed-effect model and provided a ra-
tionale for selecting this model.
Synthesis
Descriptive analysis using frequencies and percentages
were performed to summarize the characteristics of the
NMAs. Papers that relied on previous systematic reviews
to identify studies for inclusion in the NMA were cate-
gorized using content analysis by the lead author (WZ)
and verified by the study guarantor (ACT). Journal disci-
plines were coded by one reviewer (VN) using the Web
of Science journal citation reports [28]. The distribution
of NMAs by discipline was plotted in a bubble chart
using the ggplot2 library in R software [29, 30]. In order
to visualize the frequency of the terms used to describe
NMA, a word cloud was created using Wordle [31]. To
estimate the time it took to conduct each NMA, we cal-
culated the difference between the initial literature
search date and publication date using the month and
day function in Excel 2010. A Pearson correlation coeffi-
cient [32] was calculated using Excel 2010 to investigate
if a linear relationship existed between duration and
quality (according to the AMSTAR score).
Results
Literature search
The bibliographic database search yielded a total of 3727
citations (Fig. 1). After de-duplication, 3538 unique titles
and abstracts were screened and 2913 were excluded. An
additional 252 potentially relevant full-texts were identi-
fied through supplementary sources. After screening the
877 full-text articles, 456 NMAs fulfilled the eligibility cri-
teria and were included in our scoping review. The full list
of included studies can be found in Additional file 1: Ap-
pendix 3. Four papers (1%) [33–36] were reports and two
papers were non-English publications [37, 38].
Study characteristics
NMAs in our database were published between July
1999 and February 2015, with 95% (n = 432) published
after 2006 (Table 1). The majority of the NMAs were
conducted in Europe (n = 234, 51%), North America (n
= 140, 31%), and Asia (n = 67, 15%). The remaining
NMAs were conducted in Central and South America
(n = 6, 1.3%), Australia and New Zealand (n = 7, 1.5%),
and Africa (n = 2, 0.4%). Eighty percent (n = 365) of
the NMAs described the knowledge synthesis method
as a “systematic review” in either the title or the methods
section of the paper, 2% (n = 8) described the knowledge
synthesis as an “overview of reviews”, less than one per-
cent (n=1) used the term “narrative review”, and the
remaining 18% (n = 82) did not state the type of know-
ledge synthesis. The median duration from the time of the
literature search to publication was 12.5 months (inter-
quartile range (IQR), 7.2–21.8). Twelve percent (n = 55) of
the NMAs required less than 6 months to be published,
52% (n = 238) were published within 6 to 24 months,
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and 18% (n = 81) required more than 24 months to pub-
lish. We were not able to estimate duration for the
remaining NMAs (18%; n = 82) due to a lack of informa-
tion on the literature search date and/or publication date.
Most of the NMAs (n = 165, 36%) were publicly spon-
sored, 22% (n = 100) declared industry-sponsorship by a
pharmaceutical company or medical device manufac-
turer, another 22% (n = 101) reported that no external
funding was received, 2% (n=8) of the NMAs reported
both industry and public sponsorship, and 18% (n = 82)
did not disclose any funding information. The median
number of RCTs included in the knowledge synthesis
was 25 (IQR, 14–48) and the median number of
RCTs included in the NMA was 21 (IQR, 13–40).
Journal disciplines
The NMAs were published in a broad range of biomed-
ical disciplines (based on the Web of Science journal
citation reports). The five most common disciplines with
increasing growth overtime were medicine, general
and internal (n = 121), healthcare sciences and services
(n = 34), pharmacology and pharmacy (n = 33), cardiac
and cardiovascular systems (n = 29), and endocrinology
and metabolism (n = 25; Fig. 2).
Fig. 1 Study flow diagram
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Terminology and cited framework for analysis
The three most commonly used terms to describe a NMA
were “network meta-analysis” (n = 213, 47%), followed
by “mixed-treatment comparisons” (n = 108, 24%) and
“indirect comparisons” (n = 56, 12%; Additional file 1:
Appendix 4).
Most NMAs (n = 380, 83%) cited at least one previ-
ously published methodology paper to guide the analysis,
but 76 NMAs (17%) did not cite any methodology paper
for the analysis. Of the 123 unique methodology cita-
tions, the three most frequently cited papers included a
methodology paper on hierarchical Bayesian models for
NMAs (n = 137, 30%) [10], a paper providing a tutorial
on previously described NMA approaches (n = 76, 17%)
[9], and a paper on a statistical approach to generate
indirect evidence as an extension to pairwise meta-analysis
(n = 71, 16%; Additional file 1: Appendix 5) [7].
Knowledge synthesis steps
Eighteen papers (4%) did not provide sufficient informa-
tion on all of the knowledge synthesis steps and therefore
could not be characterized. The knowledge synthesis char-
acteristics for the remaining 438 NMAs are summarized
in Table 2.
Only 31% (n = 137) of the NMAs reported an a priori
protocol, but nearly all (n = 437, 99.8%) clearly reported
their research question and eligibility criteria (n = 430,
98%). Ninety-three percent (n = 407) of the NMAs
searched at least two databases, and 47% (n = 207) pro-
vided the complete literature search strategy for at least
one database. Seventy-one percent (n = 309) scanned ref-
erence lists of included studies, and 62% (n = 270)
searched for grey literature (i.e., difficult to locate or un-
published studies [39]). Conference abstracts or proceed-
ings and trial registers were the most common sources of
grey literature (133/270, 49%; Additional file 1: Appendix
6). Sixty-six percent (n = 291) of the search strategies were
limited by study design, 34% (n = 147) were limited by lan-
guage, and 31% (n = 135) were limited by date either as a
search filter or exclusion criteria.
Duplicate screening by at least two independent re-
viewers was reported in 65% (n = 285) of the NMAs for
title and abstract screening, and 64% (n = 282) for full-text
screening (Table 2). More than half (54%, n = 238) of the
NMAs completed data abstraction in duplicate, and 41%
(n = 186) assessed quality in duplicate. The most com-
monly used tool for risk of bias assessment was the
Cochrane Collaboration’s risk-of-bias tool for RCTs (147/
345, 42.6%) [40], followed by the Jadad scale [41] (75/345,
22%; Additional file 1: Appendix 7).
NMAs that relied on previously conducted systematic
reviews
Seventy-eight (17%) NMAs relied on previously con-
ducted systematic reviews to identify studies for inclu-
sion in their NMA (Table 3). More than half (n = 43) of
those NMAs updated the literature search of the system-
atic review and nearly one-fourth (n = 20) used the set of
included studies from previous systematic reviews in
their analysis (only 2 (10%) of which were from the same
group of authors). Eleven NMAs performed an updated
literature search with an expanded scope (e.g., included
additional drugs), three NMAs used the abstracted data
from previous systematic reviews, and one NMA
Table 1 Study characteristics
Study characteristics (n = 456) Count (%)
Year of publication 1999–2002 3 (0.7)
2003–2006 21 (4.6)
2007–2010 77 (16.9)
2011–2014 306 (67.1)
2015 (until April) 49 (10.7)
Geographic region Europe 234 (51.3)
North America 140 (30.7)
Asia 67 (14.7)
Central & South America 6 (1.3)
Australia & New Zealand 7 (1.5)
Africa 2 (0.4)
Knowledge synthesis
approach
Systematic review 365 (80.0)
Overview of reviews 8 (1.8)
Narrative review 1 (0.2)
Not reported 82 (18.0)
Review duration
(month)
<6 months 55 (12.1)
6–12 months 132 (28.9)
>12–24 months 106 (23.2)
>24 months 81 (17.8)
Not reported 82 (18.0)
Funding Publicly-sponsored 165 (36.2)
Industry-sponsored 100 (21.9)
Non-sponsored 101 (22.1)
Industry and publicly
sponsored
8 (1.8)
Funding source
not reported
82 (18.0)
Full review method
reporteda
Yes 438 (96.1)
No 18 (3.9)
Number of trials included
in review
Median (IQR) 25 (14–48)
Number of trials included
in the network
Median (IQR) 21 (13–40)
aNMAs without full review method were those with inadequate reporting of
review methods (i.e., literature search, study selection, data abstract and
quality assessment)
IQR interquartile range
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conducted both an updated search of the literature and
used the abstracted data from previous reviews.
AMSTAR assessment
Our assessments are based on 438 of the NMAs that
adequately reported the knowledge synthesis methods.
The knowledge synthesis methods used in 25% (n = 109)
of the NMAs were considered high quality with an
AMSTAR score of 8 or above, 57% (n = 251) were rated
as moderate quality (score 4–7), and the remaining 18%
(n = 78) were rated as low quality with an AMSTAR
score of 3 or less (Fig. 3; Additional file 1: Appendix 8).
The overall median AMSTAR score was 6 (IQR, 4–7).
The main areas of inadequate reporting that contributed
to low AMSTAR scores were lack of a protocol (69%, n
= 301), lack of a list of excluded studies from full-text
screening (82%, n = 357), and failing to clearly incorpor-
ate quality appraisal results to formulate conclusions
either because quality appraisal was not conducted or it
was conducted but not incorporated in the interpret-
ation of results (50%, n = 221). Publication bias was
assessed in only 36% (n = 158) of the NMAs and even
fewer NMAs (16%, n = 68) reported sources of funding
of the RCTs included in the knowledge synthesis.
The correlation analysis between duration and overall
AMSTAR score found no linear relationship (r = 0.014;
Additional file 1: Appendix 9). Our graph of temporal
trends suggested that the quality of reporting has im-
proved over time with increasing proportions of studies
in the “Moderate” and “High” categories (Additional
file 1: Appendix 10).
ISPOR assessment
Fifty-three percent (n = 243) of the NMAs either evalu-
ated or discussed consistency in treatment effects, and
48% (n = 218) of those networks with consistency con-
ducted a NMA that included both direct and indirect
comparisons in the analysis. Fifty-one percent (n = 231)
accounted for inconsistency or an imbalance in the
distribution of treatment effect modifiers across the
different types of comparisons in the network of RCTs, if
present. Forty-nine percent (n = 224) provided a rationale
Fig. 2 Bubble plot of NMAs published by year and journal discipline (n = 456)
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Table 2 Knowledge synthesis method characteristics
Method characteristics (n = 438)a Count (%)
A priori protocol and review design A priori protocol Use of a protocol mentioned 66 (15.1)
Published 40 (9.1)
Registered 25 (5.7)
Available upon request 6 (1.4)
Not reported 301 (68.7)
Research question Clearly reported 437 (99.8)
Unclear/inferred 1 (0.2)
Eligibility criteria Clearly reported 430 (98.2)
Unclear/inferred 1 (0.2)
Not reported 7 (1.6)
Identifying relevant studies Databases searched Searched more than one database 407 (92.9)
Searched only one database 29 (6.6)
Not reported 2 (0.5)
Search string Complete literature search 207 (47.3)
MeSH terms only 173 (39.5)
Not reported 58 (13.2)
Additional search strategy Scanned references 309 (70.5)
Grey literature searched 270 (61.6)
Consulted topic experts 80 (18.3)
Consulted librarian 67 (15.3)
Performed updated search 62 (14.2)
Manually searched selected journals 37 (8.4)
Limits applied Limited by study design 291 (66.4)
Limited by language 147 (33.6)
Limited by date 135 (30.8)
Other limits (e.g., age, humans) 129 (29.5)
Study selection Title & abstract screening Two or more independent reviewers 285 (65.1)
One reviewer and one verifier 9 (2.1)
One reviewer only 16 (3.7)
Done but unclear number of reviewers 92 (21.0)
Not reported 36 (8.2)
Full-text screening Two or more independent reviewers 282 (64.4)
One reviewer and one verifier 11 (2.5)
One reviewer only 7 (1.6)
Done but unclear number of reviewers 105 (24.0)
Not reported 33 (7.5)
Study flow Completely in PRISMA-like flow diagram 374 (85.4)
Completely in text/table only 20 (4.6)
Partially reported 15 (3.4)
Not reported 29 (6.6)
Data abstraction & quality assessment Data abstraction Two or more independent reviewers 238 (54.3)
One reviewer and one verifier 94 (21.5)
One reviewer only 8 (1.8)
Done but unclear number of reviewers 75 (17.1)
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for the choice between a fixed-effect and random-effects
model. Only 13% (n = 57) discussed the heterogeneity
assumption (i.e., choosing between network-specific
and comparison-specific heterogeneity) used for the
random-effects model, while 81% (n = 368) failed to
report this item. In the presence of heterogeneity, 56%
(n = 256) used subgroup, sensitivity or meta-regression
analysis to explore heterogeneity, and 41% (n = 187) did
not mention if heterogeneity was explored (Fig. 4).
One-fourth (n=122) of the NMAs were open loop net-
works, so the network consistency items were scored as
‘not applicable’. Two percent (n=9) of the NMAs applied
a fixed-effect model and provided a rationale for choos-
ing this model, so heterogeneity items for these were
scored as 'not applicable'. However, 4% (n = 19) of the
NMAs used a fixed-effect model without providing a ra-
tionale and more than half of these (n = 11) also failed to
report any subgroup, sensitivity or meta-regression ana-
lysis to explain heterogeneity.
Discussion
We conducted a comprehensive scoping review of 456
existing NMAs published until February 2015. The earli-
est year of publication in our database is 1999, and 95%
of the NMAs were published after 2006. This suggests
that NMA is becoming and established area of know-
ledge synthesis.
We charted the knowledge synthesis methods used to
establish the included studies in the NMAs. Although
most authors identified the review type as a systematic
review in the title or methods, many shortcuts were ob-
served. For example, one in six NMAs relied on previ-
ously conducted systematic reviews to identify RCTs to
include in their NMA and a quarter of these did not up-
date the literature search. This may be problematic as
numerous relevant and recent studies can be missed,
particularly for treatment comparisons that have never
been studied previously. Moreover, one-third of the
NMAs did not report duplicate screening of citations
and full-text articles to identify relevant studies, which is
recommended for systematic reviews [42]. Approxi-
mately two-thirds of the NMAs searched grey literature,
and one-third limited the database search by date and/or
language. Failure to search for grey literature increases
the likelihood of publication bias, but very few of the in-
cluded studies formally evaluated the presence of publi-
cation bias.
We found that the knowledge synthesis processes
underlying the NMAs were of moderate quality, but the
quality improved over time. Less than half of the NMAs
reported the literature search strategy and 30% reported
the use of a protocol. Furthermore, less than a quarter
of the NMAs were considered to be of high quality with
an AMSTAR score of 8 or greater. Areas for improve-
ment on the AMSTAR tool included use of a protocol,
assessment of publication bias, reporting of excluded
studies from full-text screening, and reporting the
sources of funding of included RCTs. Approximately
one-fifth of the NMAs were industry-sponsored, which
may pose a potential risk of funding bias [43]. Con-
versely, areas where the NMAs consistently scored well
on the AMSTAR tool included a comprehensive litera-
ture search being conducted, characteristics of included
studies being reported, and appropriate methods for
pairwise meta-analysis being applied.
We used the ISPOR tool to assess the credibility of the
analysis of NMAs and found that there is substantial
room for improvement. Most authors failed to report
the assumptions for heterogeneity used in the random-
effects model or explore reasons for heterogeneity when
Table 2 Knowledge synthesis method characteristics (Continued)
Not reported 23 (5.3)
Quality appraisal Two or more independent reviewers 181 (41.3)
One reviewer and one verifier 21 (4.8)
One reviewer only 9 (2.1)
Done but unclear number of reviewers 133 (30.4)
Not reported 94 (21.5)
a18 out of 456 NMAs did not provide details of their knowledge synthesis method
Table 3 Relying on previous reviews (n = 456)
NMAs that relied on previous review(s) Count (%)
Relying on previous reviews (n = 456)
Yes 78 (17.1)
No 378 (82.9)
Themes of use (n = 78)
Updated literature search of previous systematic review(s) 43 (55.1)
Used literature database of previous systematic review(s) 20 (25.6)
Updated and expanded literature search of previous
systematic review(s)
11 (14.1)
Used abstracted data of previous systematic review(s) 3 (3.8)
Updated literature search of previous systematic review(s)
and used data from previous reviews
1 (1.3)
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present. Half of the NMAs did not report whether assess-
ment for consistency within closed loops was done, if the
NMA combined information from both direct and indir-
ect comparisons or if inconsistencies were accounted for.
The recent publication of the PRISMA extension state-
ment for NMAs [15] may lead to improvement in quality
of reporting over time. The use of reporting guidelines
could increase methodological transparency and uptake
of research findings by allowing readers to judge the
validity and reliability of studies, and may also reduce
waste in biomedical research [44].
There are some limitations to our scoping review that
are worth noting. The correlation between duration and
AMSTAR score may be biased since we approximated the
duration based on the difference between the first litera-
ture search date and the date of publication. However,
many studies did not clearly report the first literature
search date or the publication date, as a result, the dur-
ation could not be estimated for approximately one-sixth
of the papers. Furthermore, many undocumented lags
between completion of the NMA and publication (e.g.,
journal peer-review process) could inflate this duration.
Our analysis was focused primarily on published NMAs
(in addition to few identified unpublished reports), thus,
our results may not be generalizable to all NMAs, such as
those presented at conferences or found in other unpub-
lished formats. However, given the large sample of NMAs
in our database, our findings likely represent the overall
characteristics of NMAs.
Finally, using the AMSTAR and ISPOR tools to appraise
the knowledge synthesis methods and analysis methods
for NMAs has some limitations. The AMSTAR tool was
Fig. 3 Overall AMSTAR score distribution (n = 438)
Fig. 4 ISPOR assessment by items (n = 456)
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designed and validated to assess the methodological qual-
ity of systematic reviews of RCTs [26], so it is appropriate
for NMAs of RCTs. However, some of the items on the
AMSTAR tool can be misinterpreted. For example, item 9
can be misunderstood to suggest that the choice between
a fixed-effect and a random-effects model to combine
studies be based on a test of homogeneity, which is
misguided [45, 46]. The ISPOR tool has been designed to
assess networks with at least one closed loop, which is not
always applicable to open-loop networks (i.e., adjusted or
anchored indirect comparisons). Further, the ISPOR tool
assesses whether consistency assessment is discussed, but
does not allow for the assessment of approaches that are
not valid. It inquires whether consistent networks com-
bine indirect and direct evidence, but does not cap-
ture if networks were combined inappropriately. More
guidance from the authors of the tool will be benefi-
cial to address these types of scenarios. Finally, some
of the NMAs were conducted and published before
guidance from AMSTAR or ISPOR existed, so we
acknowledge that we are judging those NMAs against
standards that were developed much later.
Conclusion
NMA is becoming an established method and its popular-
ity continues to grow. Our scoping review of 456 NMAs
revealed several reporting deficiencies and shortcuts in
the knowledge synthesis methods used. This is reflected in
the AMSTAR quality rating, with only one-quarter
assessed as being high quality. Furthermore, one in six
NMAs relied on previously conducted systematic reviews
to establish the studies included in the NMA, and a quar-
ter of these did not update the literature search. Improve-
ments in the reporting and conduct of the analytical
process for NMAs are also required. Most authors failed
to report the assumptions for heterogeneity used in the
random-effects model or explore reasons for hetero-
geneity when present. Since NMAs could be a tremen-
dously useful tool for decision-makers at all levels of the
healthcare system (e.g., patients, healthcare providers,
policymakers), it is imperative to improve reporting and
conduct in order to maximize the transparency, reprodu-
cibility, and quality of such studies. Our results suggest
that education amongst the research community is re-
quired to improve the quality of reporting and methodo-
logical quality of published NMAs. Finally, journal editors
and peer reviewers should receive adequate training to en-
sure that only the most methodologically rigorous NMAs
are published. Endorsement and implementation of
reporting guidelines, such as the PRISMA extension state-
ment for NMAs [16], by the scientific community and
journals may improve the completeness of reporting in
the future.
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